The safety of bevacizumab

Expert Opinion on Drug Safety

Volumn 5, Issue 2, 2006, Pages 289-301

  Sanborn, Rachel E ^a   Sandler, Alan B ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Bevacizumab; Monoclonal antibody; Vascular endothelial growth factor (VEGF)

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ESTRAMUSTINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEGINTERFERON; PLACEBO; THALIDOMIDE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTERY THROMBOSIS; ASPIRATION PNEUMONIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGUS HEMORRHAGE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEMATEMESIS; HEMATURIA; HEMOPTYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPONATREMIA; INTESTINE PERFORATION; KIDNEY CANCER; LETHARGY; LEUKOPENIA; LIVER DISEASE; LUNG ABSCESS; LUNG CANCER; LUNG DISEASE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG INFECTION; LUNG INFILTRATE; MALAISE; MELENA; MYALGIA; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NEUROPATHY; NEUTROPENIA; PAIN; PANCREAS CANCER; PERITONITIS; PROTEINURIA; PRURITUS; REVIEW; SENSORY NEUROPATHY; SEPSIS; SKIN TOXICITY; STOMATITIS; STROKE; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VERTEBRA FRACTURE; WOUND HEALING IMPAIRMENT; DRUG EFFECT; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY; RISK FACTOR;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; HUMANS; NEOPLASMS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33644895047     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.5.2.289     Document Type: Review

References (77)

1. TOURNIGAND C, ANDRE T, ACHILLE E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J. Clin. Oncol. (2004) 22:229-237.
2. CITRON ML, BERRY DA, CIRRINCIONE C et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. (2003) 21:1431-1439.
3. BHATIA S, ABONOUR R, PORCU P et al.: High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J. Clin. Oncol. (2000) 18:3346-3351.
4. FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182-1186.
5. SENGER DR, GALLI SJ, DVORAK AM, PERRUZZI CA, HARVEY VS, DVORAK HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 219:983-985.
6. MONTESANO R, VASSALLI J-D, BAIRD A, GUILLEMIN R, ORCI L: Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA (1986) 83:7297-7301.
7. FOLKMAN J, KLAGSBRUN M: Angiogenic factors. Science (1987) 235:442-447.
8. LEUNG DW, CACHIANES G, KUANG W-J, GOEDDEL DV, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309.
9. KECK PJ, HAUSER SD, KRIVI G et al.: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (1989) 246:1309-1312.
10. SENGER DR, CONNOLLY DT, VAN DE WATER L et al.: Purification and NH-2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. (1990) 50:1774-1778.
11. CONNOLLY DT, HEUVELMAN DM, NELSON R et al.: Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. (1989) 84:1470-1478.
12. DE VRIES C, ESCOBEDO JA, UENO H, HOUCK K, FERRARA N, WILLIAMS LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 255:989-991.
13. HOUCK KA, FERRARA N, WINER J, CACHIANES G, LI B, LEUNG DW: The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. (1991) 5:1806-1814.
14. HOUCK KA, LEUNG DW, ROWLAND AM, WINER J, FERRARA N: Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. (1992) 267:26031-26037.
15. YUAN A, YU C-J, KUO S-H et al.: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J. Clin. Oncol. (2001) 19:432-441.
16. TOKUNAGA T, OSHIKA Y, ABE Y et al.: Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer (1998) 77:998-1002.
17. MILLAUER B, WIZIGMANN-VOOS S, SCHNURCH H et al.: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 72:835-846.
18. SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis. Nature (1992) 359:843-845.
19. SUZUKI K, HAYASHI N, MIYAMOTO Y et al.: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res. (1996) 56:3004-3009.
20. PLATE KH, BREIER G, WEICH HA, RISAU W: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 359:845-848.
21. FERRARA N, WINER J, BURTON T et al.: Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells. J. Clin. Invest. (1993) 91:160-170.
22. TOI M, KASHITANI J, TOMINAGA T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int. J. Cancer (1993) 55:371-374.
23. MAEDA K, CHUNG Y-S, TAKATSUKA S et al.: Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J. Clin. Oncol. (1995) 13:477-481.
24. WEIDNER N, CARROLL PR, FLAX J, BLUMENFELD W, FOLKMAN J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. (1993) 143:401-409.
25. TOI M, HOSHINA S, TAKAYANAGI T, TOMINAGA T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer Res. (1994) 85:1045-1049.
26. TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55:3964-3968.
27. TAKAHASHI R, TANAKA S, KITADAI Y et al.: Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology (2003) 64:266-274.
28. MAEDA K, CHUNG Y-S, OGAWA Y et al.: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer (1996) 77:858-863.
29. VOLM M, KOOMAGI R, MATTERN J: Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer (1997) 74:64-68.
30. BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (Vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. (1993) 53:4727-4735.
31. BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (Vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology (1995) 26:86-91.
32. KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844.
33. KABBINAVAR FF, WONG JT, AYALA RE et al.: The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc. Am. Assoc. Cancer Res. (1995) 36:488 (Abstract 2906).
34. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.
35. BORGSTROM P, GOLD DP, HILLAN KJ, FERRARA N: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anti-Cancer Res. (1999) 19:4203-4214.
36. GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. (2001) 19:843-850.
37. MARGOLIN K, GORDON MS, HOLMGREN H et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J. Clin. Oncol. (2001) 19:851-856.
38. LANGMUIR VK, COBLEIGH MA, HERBST RS et al.: Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstract 32.
39. SLEDGE G, MILLER K, NOVOTNY W et al.: A Phase II trial of single-agent Rhumab VEGF (Recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:Abstract 5C.
40. COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol. (2003) 30:117-124.
41. MILLER KD, WANG M, GRALOW J et al.: A randomized Phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Proceedings of the San Antonio Breast Cancer Symposium (2005) Abstract 3.
42. YANG JD, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
43. JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184-2191.
44. SANDLER AB, GRAY R, BRAHMER J et al.: Randomized Phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer: An Eastern Cooperative Oncology Group trial-E4599. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4.
45. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
46. GRAY R, GIANTONIO BJ, O'DWYER PJ et al.: The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: The Eastern Cooperative Oncology Group's (ECOG) experience with bevacizumab (anti-VEGF). Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 825.
47. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
48. HAMBLETON J, NOVOTNY WF, HURWITZ H et al.: Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 3528.
49. SCAPPATICCI F, FEHRENBACHER L, CARTWRIGHT T et al.: Lack of effect of bevacizumab on wound healing/bleeding complications when given 28-60 days following primary cancer surgery. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 3530.
50. HURWITZ H, FEHRENBACHER L, CARTWRIGHT T et al.: Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 3702.
51. KOZLOFF M, COHN A, CHRISTIANSEN N et al.: Safety of bevacizumab among patients receiving first-line chemotherapy for metastatic colorectal cancer: Preliminary results from a larger registry in the US. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3566.
52. KABBINAVAR FF, SCHULZ J, MCCLEOD M et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized Phase II trial. J. Clin. Oncol. (2005) 23:3697-3705.
53. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group study E3200. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 2.
54. SKILLINGS JR, JOHNSON DH, MILLER K et al.: Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials of bevacizumab with chemotherapy. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3019.
55. HAMBLETON J, SKILLINGS J, KABBINAVAR F et al.: Safety of low-dose aspirin in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3554.
56. HOCHSTER HS, WELLES L, HART L et al.: Safety and efficacy of bevacizumab when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1 & 2 studies. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3515.
57. BURGER RA, SILL M, MONK BJ et al.: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 5009.
58. STOPECK AT, BELLAMY W, UNGER J et al.: Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin's lymphoma: Southwest Oncology Group Study S0108. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 6592.
59. SCHWARTZ JD, SCHWARTZ M, LEHRER D et al.: Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4122.
60. RAEFSKY EL, SPIGEL DR, GRECO FA et al.: Irinotecan, carboplatin, and radiotherapy followed by bevacizumab in the treatment of limited-stage small cell lung cancer: A Phase II trial of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 7050.
61. PICUS J, HALABI S, RINI B et al.: The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 1578.
62. KINDLER HL, KARRISON T, LU C et al.: A multicenter, double-blind, placebo-controlled randomized Phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 7019.
63. ZHU AX, SAHANI D, NORDENZFONI A et al.: A Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4120.
64. YAO JC, NG C, HOFF PM et al.: Improved progression free survival, and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4007.
65. SHAH MA, ILSON D, RAMANATHAN RK et al.: A multicenter Phase II study of irinotecan, cisplatin, and bevacizumab in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4025.
66. FERNANDO N, YU D, MORSE M et al.: A Phase II study of oxaliplatin, capecitabine, and bevacizumab in the treatment of metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3556.
67. CRANE CH, ELLIS LM, ABBRUZZESE JL et al.: Phase I trial of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 4033.
68. WILLETT CG, CHUNG D, SAHANI D et al.: Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 3589.
69. KINDLER HL, FRIBERG G, STADLER WM et al.: Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center Phase II trial. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 4009.
70. CHEN HX, MOONEY M, BORON M et al.: Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 3515.
71. OVERMOYER B, SILVERMAN P, LEEMING R et al.: Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 727.
72. HAINSWORTH JD, SOSMAN JA, SPIGEL DR, EDWARDS DL, BAUGHMAN C, GRECO A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. (2005) 23:7889-7896.
73. SANDLER AB, BLUMENSCHEIN GR, HENDERSON T et al.: Phase I/II trial evaluating the anti-VEGF Mab bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 2000.
74. VOKES EE, COHEN EE, MAUER AM et al.: A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 5504.
75. GRECO FA, SPIGEL DR, SHIPLEY DL et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic carcinoma of unknown primary site: A Sarah Cannon Research Institute Phase II trial. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstract 3088.
76. DICKLER M, RUGO H, CARAVELLI J et al.: Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 2001.
77. SALTZ LB, LENZ H, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:3508.